Vitek characterisation of type 2 diabetes-associated Candida species

Simple item page
dc.contributor.authorEsmaio, Mustafa Hassan Mustafa
dc.contributor.authorAbrantes, Pedro Miguel dos Santos
dc.contributor.authorAfrica, Charlene Wilma Joyce
dc.date.accessioned2019-03-05T12:57:02Z
dc.date.available2019-03-05T12:57:02Z
dc.date.issued2017
dc.description.abstractBackground: Type 2 diabetes mellitus (T2DM) predisposes patients to opportunistic infections, such as invasive candidiasis. Treatment of candidiasis is challenged by the emerging resistance of Candida species. In this study, the antifungal drug resistance patterns of Candida species present in the oral mucosa of T2DM Libyan patients was investigated. Methods: Seventy four (74) oral Candida isolates collected from T2DM patients in Misrata, Libya were characterised using the VITEK 2 Compact system. Results: Prevalent species included C. albicans, C. glabrata, C. dubliniensis, C. krusei, C. tropicalis, C. sake, C. kefyr, C. guilliermondii, C. parapsilopsis, C. membranifaciens and C. magnoliae. Drug susceptibility showed an emerging resistance across representatives of all species for which breakpoints were available, with the exception of C. parapsilopsis. Although there are no established interpretative breakpoints for these species, three C. sake isolates and the C. membranifaciens isolate also had high MIC values for fluconazole. The tested isolates were found to be largely susceptible to caspofungin and micafungin. All C. albicans isolates were susceptible to the echinocandins, amphotericin B and 5-flucytosine. Resistance to more than one drug class was seen in C. dubliniensis, C. glabrata and C. krusei isolates. Conclusion: Although the susceptibility results for the echinocandins were encouraging, resistance against the azoles was apparent and should not be ignored. This was especially so in the case of fluconazole, which is often the only locally available antifungal drug for the treatment of disseminated candidiasis.en_US
dc.description.sponsorshipThis study was supported financially by the Libyan Government.en_US
dc.identifier.citationEsmaio MHM, et al. (2017) Vitek characterisation of type 2 diabetes-associated Candida species. International Journal of Antimicrobial Agents. September 2017; 50 (Suppl 1): S118en_US
dc.identifier.issn0924-8579
dc.identifier.urihttp://hdl.handle.net/10566/4333
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectCandidaen_US
dc.subjectAntifungal drug resistanceen_US
dc.subjectLibyaen_US
dc.titleVitek characterisation of type 2 diabetes-associated Candida speciesen_US
dc.typePresentationen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Korea ISAAR-ICIC 2017 Poster.pdf
Size:
457.16 KB
Format:
Adobe Portable Document Format
Description:
Poster presentation
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Conference Papers (Medical Bioscience)